Tolmetin
CAS No. 26171-23-3
Tolmetin( —— )
Catalog No. M13798 CAS No. 26171-23-3
Tolmetin is a Nonsteroidal Anti-inflammatory Drug. The mechanism of action of tolmetin is as a Cyclooxygenase Inhibitor.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 25MG | 35 | In Stock |
|
| 50MG | 50 | In Stock |
|
| 100MG | Get Quote | In Stock |
|
| 200MG | Get Quote | In Stock |
|
| 500MG | Get Quote | In Stock |
|
| 1G | Get Quote | In Stock |
|
Biological Information
-
Product NameTolmetin
-
NoteResearch use only, not for human use.
-
Brief DescriptionTolmetin is a Nonsteroidal Anti-inflammatory Drug. The mechanism of action of tolmetin is as a Cyclooxygenase Inhibitor.
-
DescriptionTolmetin is a Nonsteroidal Anti-inflammatory Drug. The mechanism of action of tolmetin is as a Cyclooxygenase Inhibitor. The chemical classification of tolmetin is Nonsteroidal Anti-inflammatory Compounds.(In Vitro):Tolmetin (0.25 mM) does not attenuate lipid peroxidation in rat brain homogenate. Tolmetin (0.25, 0.5, 0.75, 1 mM) shows radical scavenging properties but without superoxide anion generation in rat brain homogenat.Tolmetin (0.001-100 μM) shows anticancer activity againts HT-29 colon cancer cell line in a dose-dependent manner.Tolmetin (0-100 μM) shows no effect on osteoblast growth.(In Vivo):Tolmetin (30,100 mg/kg; gavage; single dose or twice daily for 3 and 14 days) shows maximal ulcerogenic effect 4 h after the single dose, while potently decreases after 3 and 14 days of repeated administration in male Wistar rats weighing 180-200 g. Tolmetin causes gastric lesions in 100 mg/kg.Tolmetin (5 mg/kg twice a day for 5 days) pre-treatment considerably attenuates quinolinic acid (QA)-induced neurotoxicity.
-
In VitroTolmetin (0.25 mM) does not attenuate lipid peroxidation in rat brain homogenate. Tolmetin (0.25, 0.5, 0.75, 1 mM) shows radical scavenging properties but without superoxide anion generation in rat brain homogenat. Tolmetin (0.001-100 μM) shows anticancer activity againts HT-29 colon cancer cell line in a dose-dependent manner.
-
In VivoTolmetin (30,100 mg/kg; gavage; single dose or twice daily for 3 and 14 days) shows maximal ulcerogenic effect 4 h after the single dose, while potently decreases after 3 and 14 days of repeated administration in male Wistar rats weighing 180-200 g. Tolmetin causes gastric lesions in 100 mg/kg. Tolmetin (5 mg/kg twice a day for 5 days) pre-treatment considerably attenuates quinolinic acid (QA)-induced neurotoxicity.
-
Synonyms——
-
PathwayChromatin/Epigenetic
-
TargetCOX
-
RecptorCOX-1| COX-2
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number26171-23-3
-
Formula Weight257.28
-
Molecular FormulaC15H15NO3
-
Purity>98% (HPLC)
-
SolubilityDMSO: 10 mM
-
SMILESCN1C(CC(O)=O)=CC=C1C(=O)C1=CC=C(C)C=C1
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1.Burdan F, et al. Pharmacol Res. 2004 Nov;50(5):533-43.
molnova catalog
related products
-
Feladilimab
Feladilimab (GSK3359609) is an IgG4 monoclonal antibody that is an ICOS agonist.
-
Acacetin
Acacetin has anti-plasmodial activity and anti-peroxidant activity.
-
Sodium [(2,3-dihydro...
A drug that has analgesic, anti-inflammatory, and antipyretic properties. It is the sodium sulfonate of aminopyrine.
Cart
sales@molnova.com